2.52Open2.52Pre Close0 Volume482 Open Interest340.00Strike Price0.00Turnover98.21%IV35.38%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry2.52Extrinsic Value100Contract SizeAmericanOptions Type0.1053Delta0.0033Gamma100.40Leverage Ratio-0.2814Theta0.0116Rho10.57Eff Leverage0.1013Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet